Exelixis Inc. Stock
Exelixis Inc. Stock
A very strong showing by Exelixis Inc. today, with an increase of €1.16 (3.220%) compared to yesterday's price.
The stock is one of the favorites of our community with 31 Buy predictions and 1 Sell predictions.
As a result the target price of 41 € shows a slightly positive potential of 10.84% compared to the current price of 36.99 € for Exelixis Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Exelixis Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Exelixis Inc. in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Exelixis Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Exelixis Inc. | 3.220% | -0.431% | -2.324% | 12.159% | -3.972% | 124.073% | 104.455% |
| Iovance Biotherapeutics Inc. | 1.300% | 1.119% | 7.698% | -57.480% | -8.579% | -67.596% | -94.590% |
| United Therapeutics | -0.270% | -2.386% | -2.100% | 13.149% | -6.155% | 68.134% | 184.397% |
| Neurocrine Bioscience | 1.490% | -12.474% | -7.926% | -6.485% | -14.338% | 8.286% | 11.082% |
Comments
Exelixis (NASDAQ:EXEL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $52.00 price target on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at HC Wainwright from $49.00 to $52.00. They now have a "buy" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Show more
Ratings data for EXEL provided by MarketBeat
News
Exelixis Reports Solid Earnings—Are New Highs Back on the Table?
Exelixis Inc. (NASDAQ: EXEL) stock is down about 2% in early trading the day after the company delivered a solid, but mixed earnings report. The company reported earnings per share (EPS) of 94
2 Stocks That Could Soar This Year
In the volatile biotech industry, companies can see their shares soar over relatively short periods on strong clinical progress for exciting pipeline candidates.
That's precisely what could happen
2 Healthcare Stocks to Buy for 2026 and Beyond
The healthcare sector underperformed broader equities in 2025, but that shouldn't deter investors. Many companies in the industry performed relatively well and appear to be solid buy-and-hold